ArticleFrontiers in oncology2022

Case Report: Recombinant Human Endostatin Plus Chemotherapy for Epidermal Growth Factor Receptor-Negative Miliary Lung Adenocarcinoma.

Jian Zhu et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.